Form 4: Plus Therapeutics Director Acquires Additional Shares

Director Richard J Hawkins purchased 4,000 shares of Plus Therapeutics at an average price of $1.499 on September 13, 2024.

Summary

• On September 13, 2024, Richard J Hawkins, a director of Plus Therapeutics, acquired 4,000 shares of common stock.
• The shares were purchased at a weighted average price of $1.499 per share, with individual transactions ranging from $1.47 to $1.50.
• Following the transaction, Hawkins directly owns 15,188 shares of Plus Therapeutics.
• The transaction was reported on September 17, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director purchasing shares suggests confidence, but the transaction is relatively small and doesn't provide a strong signal.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade in their company's stock. It provides transparency to the market regarding insider transactions.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Plus Therapeutics, Director, Share Acquisition, Richard J Hawkins, PSTV, Common Stock, Beneficial Ownership